February 2019 – Kinstellar has successfully advised Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the treatment of central nervous system disorders (CNS), part of the APAX portfolio group of companies, on the acquisition of Farmax, a CNS specialty pharmaceutical company, from SVUS Pharma, in the Czech Republic, Slovakia and Hungary. Farmax is a leader in sales and marketing of both branded and non-branded generic pharmaceuticals for CNS disorders. The terms of the transaction were not disclosed.
Kinstellar’s team was led by Lukáš Ševčík (Partner). Other key members included Tereza Naučová and Adam Němec (Senior Associates), Martin Holub (Associate), Michal Matouš, Tereza Mašková and Václav Kment (Junior Associates).
For more information please contact Lukáš Ševčík at .